Literature DB >> 24413893

Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer.

R Bütof1, K Kirchner, S Appold, S Löck, A Rolle, G Höffken, M Krause, M Baumann.   

Abstract

AIM: The aim of this analysis was to investigate the impact of tumour-, treatment- and patient-related cofactors on local control and survival after postoperative adjuvant radiotherapy in patients with non-small cell lung cancer (NSCLC), with special focus on waiting and overall treatment times. PATIENTS AND METHODS: For 100 NSCLC patients who had received postoperative radiotherapy, overall, relapse-free and metastases-free survival was retrospectively analysed using Kaplan-Meier methods. The impact of tumour-, treatment- and patient-related cofactors on treatment outcome was evaluated in uni- and multivariate Cox regression analysis.
RESULTS: No statistically significant difference between the survival curves of the groups with a short versus a long time interval between surgery and radiotherapy could be shown in uni- or multivariate analysis. Multivariate analysis revealed a significant decrease in overall survival times for patients with prolonged overall radiotherapy treatment times exceeding 42 days (16 vs. 36 months) and for patients with radiation-induced pneumonitis (8 vs. 29 months).
CONCLUSION: Radiation-induced pneumonitis and prolonged radiation treatment times significantly reduced overall survival after adjuvant radiotherapy in NSCLC patients. The negative impact of a longer radiotherapy treatment time could be shown for the first time in an adjuvant setting. The hypothesis of a negative impact of longer waiting times prior to commencement of adjuvant radiotherapy could not be confirmed.

Entities:  

Mesh:

Year:  2014        PMID: 24413893     DOI: 10.1007/s00066-013-0501-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  42 in total

1.  [Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation].

Authors:  Thomas Herrmann; Michael Baumann
Journal:  Strahlenther Onkol       Date:  2005-02       Impact factor: 3.621

2.  Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.

Authors:  M Guckenberger; A Kavanagh; M Partridge
Journal:  Strahlenther Onkol       Date:  2012-08-31       Impact factor: 3.621

3.  Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment.

Authors:  F Manapov; S Klöcking; M Niyazi; C Belka; G Hildebrandt; R Fietkau; G Klautke
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

4.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

5.  The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

Authors:  Howard D Thames; Deborah Kuban; Larry B Levy; Eric M Horwitz; Patrick Kupelian; Alvaro Martinez; Jeffrey Michalski; Thomas Pisansky; Howard Sandler; William Shipley; Michael Zelefsky; Anthony Zietman
Journal:  Radiother Oncol       Date:  2010-04-17       Impact factor: 6.280

Review 6.  Monoclonal antibodies against EGFR in non-small cell lung cancer.

Authors:  Robert Pirker; Martin Filipits
Journal:  Crit Rev Oncol Hematol       Date:  2010-11-24       Impact factor: 6.312

7.  [ZD1839 (Iressa) in the treatment of non-small cell lung cancer patients].

Authors:  Xiaotong Zhang; Longyun Li; Xinlin Mu; Shulan Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2004-08-20

8.  Tumor volume: a basic and specific response predictor in radiotherapy.

Authors:  H H Dubben; H D Thames; H P Beck-Bornholdt
Journal:  Radiother Oncol       Date:  1998-05       Impact factor: 6.280

Review 9.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

10.  Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy.

Authors:  J J Jobsen; J van der Palen; M Baum; M Brinkhuis; H Struikmans
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

View more
  7 in total

1.  Postoperative radiotherapy of patients with thymic epithelial tumors (TET): a retrospective analysis of outcome and toxicity.

Authors:  Matthias Felix Häfner; Falk Roeder; Florian Sterzing; David Krug; Stefan A Koerber; Jutta Kappes; Hans Hoffmann; Alla Slynko; Jürgen Debus; Marc Bischof
Journal:  Strahlenther Onkol       Date:  2014-08-26       Impact factor: 3.621

2.  Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer.

Authors:  Ugur Selek; Joe Y Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.

Authors:  John L Mikell; Theresa W Gillespie; William A Hall; Dana C Nickleach; Yuan Liu; Joseph Lipscomb; Suresh S Ramalingam; Raj S Rajpara; Seth D Force; Felix G Fernandez; Taofeek K Owonikoko; Rathi N Pillai; Fadlo R Khuri; Walter J Curran; Kristin A Higgins
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy.

Authors:  Annemarie F Shepherd; Michelle Iocolano; Jonathan Leeman; Brandon S Imber; Aaron T Wild; Michael Offin; Jamie E Chaft; James Huang; Andreas Rimner; Abraham J Wu; Daphna Y Gelblum; Narek Shaverdian; Charles B Simone; Daniel R Gomez; Ellen D Yorke; Andrew Jackson
Journal:  Pract Radiat Oncol       Date:  2020-10-14

5.  PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial.

Authors:  R Bütof; M Simon; S Löck; E G C Troost; S Appold; M Krause; M Baumann
Journal:  Trials       Date:  2017-12-20       Impact factor: 2.279

6.  Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.

Authors:  Liming Sheng; Xiaoying Cui; Lei Cheng; Ying Chen; Xianghui Du
Journal:  Radiat Oncol       Date:  2019-12-16       Impact factor: 3.481

Review 7.  Radiation-Induced Lung Injury-Current Perspectives and Management.

Authors:  Mandeep Singh Rahi; Jay Parekh; Prachi Pednekar; Gaurav Parmar; Soniya Abraham; Samar Nasir; Rajamurugan Subramaniyam; Gini Priyadharshini Jeyashanmugaraja; Kulothungan Gunasekaran
Journal:  Clin Pract       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.